Niraparib Exhibits a Synergistic Anti-Tumor Effect with PD-L1 Blockade by Inducing an Immune Response in Ovarian Cancer

Programmed death ligand 1 (PD-L1) expression in human ovarian cancer cells after PARP inhibitors treatment was examined by western blotting and flow cytometry.
[Journal of Translational Medicine]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Germline Variants in DNA Repair Genes, including BRCA1/2, May Cause Familial Myeloproliferative Neoplasms

Investigators demonstrated the relevance of genetic germline diagnostics in elucidating the causes of myeloproliferative neoplasms (MPNs) and suggested novel therapeutic options in MPNs.
[Blood Advances]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Synergistic Targeting of BRCA1 Mutated Breast Cancers with PARP and CDK2 Inhibition

In cell lines, BRCA1 loss was associated with stabilized cyclin E1 during the cell cycle, and BRCA1 siRNA led to increased cyclin E1 in association with reduced phospho-cyclin E1 T62.
[npj Breast Cancer]
[zotpress userid=’7992332′ items=’LVJ2LSCB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Cell-Autonomous Inflammation of BRCA1-Deficient Ovarian Cancers Drives Both Tumor-Intrinsic Immunoreactivity and Immune Resistance via STING

Genetic deletion or methylation of DNA-sensing/IFN genes or CCL5 chemokine was identified as a potential mechanism to attenuate T cell inflammation.
[Cell Reports]
[zotpress userid=” items=’LE78Y4RB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Understanding and Overcoming Resistance to PARP Inhibitors in Cancer Therapy

Scientists summarize the diverse processes underlying resistance to poly(ADP-ribose) polymerase (PARP) inhibitors and discuss the potential strategies that might overcome these mechanisms such as combinations with chemotherapies, targeting the acquired vulnerabilities associated with resistance to PARP inhibitors or suppressing genomic instability.
[Nature Reviews Clinical Oncology]
[zotpress userid=’7992332′ items=’ENVKZMG6′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer

Using a combination of in vivo and in vitro analyses in a novel PyMT-E2A conditional knockout mouse model and derived primary tumor cell lines, researchers reported an essential role of E2A in stemness, metastasis, and therapeutic resistance in breast cancer.
[Cancer Research]
[zotpress userid=” items=’6XJ2RWYD’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Oct4 Confers Stemness and Radioresistance to Head and Neck Squamous Cell Carcinoma by Regulating the Homologous Recombination Factors PSMC3IP and RAD54L

Investigators provided evidence that the CSC-related transcription factor Oct4 contributes to head and neck squamous cell carcinoma radioresistance by regulating DNA damage response and the CSC phenotype.
[Oncogene]
[zotpress userid=” items=’WVNMWLMG’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Interfaces between Cellular Responses to DNA Damage and Cancer Immunotherapy

Scientists review the current understanding of the molecular mechanisms underlying DNA damage-triggered immune responses, including cytosolic DNA sensing via the cGAS/STING pathway.
[Genes & Development]
[zotpress userid=’6445218′ items=’5XKFFALH’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Resistance to Second-Generation Androgen Receptor Antagonists in Prostate Cancer

Ongoing research to establish predictive biomarkers for the treatment of tumors with resistance to second-generation androgen receptor antagonists led to the approval of the PARP inhibitors olaparib and rucaparib in pre-treated metastatic castration-resistant prostate cancer.
[Nature Reviews Urology]
[zotpress userid=’6807162′ items=’GBJDIUM7′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Synergistic Effects of Type I PRMT and PARP Inhibitors against Non-Small Cell Lung Cancer Cells

The combination of MS023, a type I protein arginine methyltransferases (PRMT) inhibitor, and the PARP inhibitor BMN-673 demonstrated strong synergistic interaction at low nanomolar concentrations in methylthioadenosine phosphorylase-negative NSCLC cell lines A549, SK-LU-1 and HCC4006.
[Clinical Epigenetics]
[zotpress userid=’6606345′ items=’CEQLNDLR’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Loss of BRCA1 Expression and Morphological Features Associated with BRCA1 Promoter Methylation Status in Triple-Negative Breast Cancer

The authors investigated the possibility to predict BRCA1 promoter methylation status based on the morphological and immunohistochemical features of TNBCs.
[Journal of Human Genetics]
[zotpress userid=’6807162′ items=’R4NRI79W’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share